Evidence map›Paper›PMID 38534392›Full record

ArticleCells2024

Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration.

Yujong Yi, Seon-Hong Pyun, Chae-Yeon Kim, Gyeongju Yun, Eunhwa Kang, Seoyoun Heo, Irfan Ullah, Sang-Kyung Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yujong YiDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.ORCID 0009-0006-6660-5194
Seon-Hong PyunDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.
Chae-Yeon KimDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.
Gyeongju YunDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.ORCID 0009-0005-4237-1621
Eunhwa KangDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.
Seoyoun HeoDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.
Irfan UllahDepartment of Internal Medicine, Yale University, New Haven, CT 06520, USA.ORCID 0000-0002-7760-8693
Sang-Kyung LeeDepartment of Bioengineering and Institute of Nanoscience and Technology, Hanyang University, Seoul 04763, Republic of Korea.ORCID 0000-0002-1680-7218
Hanyang University · KRYale University · US

Funding

Korea Research Foundation 2022R1A2C1011348
6 · The paper itself

Abstract

Age-related macular degeneration (AMD), characterized by macular retinal degeneration, poses a significant health concern due to the lack of effective treatments for prevalent dry AMD. The progression of AMD is closely linked to reactive oxygen species and Fas signaling, emphasizing the need for targeted interventions. In this study, we utilized a NaIO

Indexed as

Macular DegenerationRetinal DegenerationAnimalsHumansInflammationMiceOphthalmic SolutionsPeptidesRabbitsOphthalmic SolutionsPeptidesage-related macular degeneration (AMD)anti-VEGF agentsapoptosisdry AMDeye dropsFas-blocking peptidenecrosisretinavascular endothelial growth factor (VEGF) inhibitorswet AMD

Identifiers

PMID38534392
PMCPMC10969560
OpenAlexW4392985354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.